Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Doorman who wrote (13881)	2/23/1999 4:02:00 PM
From: Justin Curran	Read Replies (2) \| Respond to of 122088

ENMD... Most analysts who spoke to Dow Jones credited EntreMed's 19% rise Tuesday with the Boston Globe article. But Carl L. Gordon, an analyst with OrbiMed Advisors in New York, wasn't so impressed with the story. "It's nice to reduce tumor growth in mice," he told Dow Jones. "But there are big unknowns between that and humans. It's hard to get excited about mice cancer data." Rather, Gordon blamed the financial media for generating interest in a company that's not so interesting. "I don't know why anyone pays so much attention to it but you guys," Gordon said. "There's 500 biotech companies out there and they're all doing interesting stuff. EntreMed's up because you guys make it go up." Eric Ende, an analyst with Lehman Brothers in New York, said the stock could partially be up because some investors are "short covering." "A lot of people came in and shorted the stock a few weeks ago," he said. "But it could be the Boston Globe piece that's pushing it up, too."